Daewoong Pharmaceutical Bilan de santé

Santé financière contrôle des critères 3/6

Daewoong Pharmaceutical possède un total de capitaux propres de ₩951.4B et une dette totale de ₩614.9B, ce qui porte son ratio d'endettement à 64.6%. Son actif total et son passif total sont ₩1,922.5B et de ₩971.1B. L'EBIT de Daewoong Pharmaceutical est ₩136.5B ce qui fait que son ratio de couverture des intérêts 34.5. Elle dispose de liquidités et de placements à court terme de ₩107.5B.

Informations clés

64.6%

Ratio d'endettement

₩614.89b

Dette

Ratio de couverture des intérêts	34.5x
Argent liquide	₩107.51b
Fonds propres	₩951.35b
Total du passif	₩971.10b
Total des actifs	₩1.92t

Mises à jour récentes de la santé financière

Daewoong Pharmaceutical (KRX:069620) Seems To Use Debt Quite Sensibly

Oct 15

We Think Daewoong Pharmaceutical (KRX:069620) Can Stay On Top Of Its Debt

Jul 04

Recent updates

Impressive Earnings May Not Tell The Whole Story For Daewoong Pharmaceutical (KRX:069620)

Nov 22

There's Reason For Concern Over Daewoong Pharmaceutical Co., Ltd's (KRX:069620) Price

Nov 06

Daewoong Pharmaceutical (KRX:069620) Seems To Use Debt Quite Sensibly

Oct 15

Daewoong Pharmaceutical Co., Ltd (KRX:069620) Shares Could Be 49% Below Their Intrinsic Value Estimate

Aug 13

Daewoong Pharmaceutical Co., Ltd's (KRX:069620) 27% Price Boost Is Out Of Tune With Earnings

Jul 24

We Think Daewoong Pharmaceutical (KRX:069620) Can Stay On Top Of Its Debt

Jul 04

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de A069620 ( ₩574.2B ) dépassent ses passifs à court terme ( ₩538.1B ).

Passif à long terme: Les actifs à court terme de A069620 ( ₩574.2B ) dépassent ses passifs à long terme ( ₩433.0B ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de A069620 ( 53.3% ) est considéré comme élevé.

Réduire la dette: Le ratio d'endettement de A069620 est passé de 61.7% à 64.6% au cours des 5 dernières années.

Couverture de la dette: La dette de A069620 n'est pas bien couverte par le flux de trésorerie opérationnel ( 6.9% ).

Couverture des intérêts: Les paiements d'intérêts de A069620 sur sa dette sont bien couverts par l'EBIT ( 34.5 x couverture).

Daewoong Pharmaceutical Bilan de santé

Santé financière contrôle des critères 3/6

Informations clés

Mises à jour récentes de la santé financière

Daewoong Pharmaceutical (KRX:069620) Seems To Use Debt Quite Sensibly

We Think Daewoong Pharmaceutical (KRX:069620) Can Stay On Top Of Its Debt

Recent updates

Impressive Earnings May Not Tell The Whole Story For Daewoong Pharmaceutical (KRX:069620)

There's Reason For Concern Over Daewoong Pharmaceutical Co., Ltd's (KRX:069620) Price

Price target increased by 7.8% to ₩190,000

Price target increased by 11% to ₩176,250

Daewoong Pharmaceutical (KRX:069620) Seems To Use Debt Quite Sensibly

Investor sentiment improves as stock rises 15%

Investor sentiment improves as stock rises 19%

Daewoong Pharmaceutical Co., Ltd (KRX:069620) Shares Could Be 49% Below Their Intrinsic Value Estimate

Daewoong Pharmaceutical Receives Positive Recommendation from IDMC to Continue Developing its First-In-Class PRS Inhibitor, Bersiporocin

Daewoong Pharmaceutical Co., Ltd's (KRX:069620) 27% Price Boost Is Out Of Tune With Earnings

Investor sentiment improves as stock rises 19%

We Think Daewoong Pharmaceutical (KRX:069620) Can Stay On Top Of Its Debt

Consensus EPS estimates increase by 25%

High number of new and inexperienced directors

New major risk - Revenue and earnings growth

Upcoming dividend of ₩600 per share at 0.5% yield

Daewoong Pharmaceutical Announces Successful 'Extra Strength' Results of US Phase 2 Clinical Trial for High-Dose Administration of Nabota

Daewoong Pharmaceutical to Initiate Clinical Trials Early Next Year for Innovative GLP-1 Obesity Treatment with Advanced Microneedle Technology for Sustained Weekly Efficacy

Daewoong Therapeutics Gets Mfds Nod for Phase 1 Ind for the World's First Eyedrop Treatment for Diabetic Retinopathy and Macular Edema

Price target decreased by 7.5% to ₩171,083

Daewoong Pharmaceutical Obtains Approval for SGLT2i + Metformin Combination Drug Envlomet

New minor risk - Shareholder dilution

Avacta Group Plc (AIM:AVCT) acquired Unknown minority stake in AffyXell Therapeutics Co., Ltd. from Daewoong pharmaceutical Co.,Ltd (KOSE:A069620).

Daewoong Pharmaceutical Presents New Clinical Data of Fexuprazan at Digestive Disease Week 2023

Full year 2022 earnings released: EPS: ₩3,816 (vs ₩2,227 in FY 2021)

Now 20% undervalued after recent price drop

Price target decreased by 7.4% to ₩205,714

Investor sentiment deteriorates as stock falls 18%

Daewoong Pharmaceutical Begins the First Administration of Bersiporocin

Daewoong Pharmaceutical Co.,Ltd Submits NDA for Its Global New Drug Fexuclue in 11 Countries, Only 1 Year After Approval in Korea

Consensus forecasts updated

Upcoming dividend of ₩600 per share

Daewoong Pharmaceutical Announces Success in Developing New Antidiabetic Medication

Now 20% undervalued after recent price drop

Less than half of directors are independent

Daewoong Pharmaceutical Announces Phase 3 Clinical Trial Results of New Diabetes Treatment Enavogliflozin

Investor sentiment improved over the past week

Price target increased to ₩235,714

Daewoong Pharmaceutical Announces US FDA Clearance of IND Application for DWP213388, First-In-Class Irreversible Oral Dual Acting Inhibitor for Autoimmune Diseases

Price target increased to ₩235,000

Daewoong Pharmaceutical Gets First Korean US FDA Fast-Track for New Idiopathic Pulmonary Fibrosis Drug

Investor sentiment improved over the past week

Less than half of directors are independent

Daewoong Pharmaceutical Submits NDA for its Global New Drug Fexuclue Tablets to the Philippines

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Daewoong pharmaceutical Co.,Ltd Announces Successful Phase 3 Topline Results for New Antidiabetic Drug's Triple Combination Therapy

Daewoong Pharmaceutical Released Positive Phase 3 Topline Results for New Antidiabetic Drug

Upcoming dividend of ₩600 per share

Price target increased to ₩199,000

Daewoong Pharmaceutical Publishes Results of First Clinical Study of SGLT-2 Inhibitor 'Enavogliflozin' for Canine Diabetes

Daewoong Pharmaceutical of South Korea Announces PRS-Inhibitor for Idiopathic Pulmonary Fibrosis Shows Promising Result in Early Stage Clinical Test

First quarter 2021 earnings released: ₩2,139 loss per share (vs ₩65.00 profit in 1Q 2020)

Price target increased to ₩147,143

Evolus, Inc. and Daewoong Pharmaceuticals Co., Ltd. Enter into Settlement Agreement

Full year 2020 earnings released: EPS ₩1,196 (vs ₩2,132 in FY 2019)

Daewoong pharmaceutical Co.,Ltd., Annual General Meeting, Mar 26, 2021

New 90-day low: ₩121,000

Price target raised to ₩126,625

New 90-day high: ₩119,000

Third quarter 2020 earnings released: EPS ₩223

Price target lowered to ₩110,000

New 90-day low: ₩91,900

Daewoong Pharmaceutical Announces Korea's First-Ever SGLT2 Inhibitor for Diabetes Treatment

Price target lowered to ₩123,214

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines